Abstract: Prosthetic apparatuses with probiotic microorganisms to control colonization of pathogenic bacteria are disclosed. The prosthetic apparatus may include a first portion having a first mating surface, a second portion having a second mating surface that conforms to the first mating surface, and at least one strain of probiotic microorganisms retained between the first and second mating surfaces prior to implantation of the prosthetic apparatus.

Abstract: The invention relates to the use of at least one probiotic microorganism as an active agent for preventing and/or treating impairments of the skin's microrelief.

Abstract: The disclosure describes fungal organisms and preparations useful for inhibiting infection by Xylella sp. and in the treatment of Pierce's Disease.

Abstract: Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD.

Abstract: The present invention relates to method of treating distal gastrointestinal diseases including infections, inflammations and functional motility disorders by oral administration of therapeutic or preventive biologic agent that is released directly to the disease area in the distal ileum, ileacecal junction or colon. The biologic agent may include live or dormant bacteria or other organism, e.g. yeast, or other biologic agent. The delivery vehicle must prevent release of the biologic agent in the upper segments of the gastrointestinal tract where it may lose its potency or decrease in quantity.

Abstract: This invention provides a method of using red yeast rice fermented product to treat a subject having a disease caused by dengue virus. In one embodiment, the red yeast rice is prepared with the yeast Monascus purpureus.

Abstract: The present invention relates to multi purpose herbal cattle feed supplement compositions for enhancing the productivity and quality of milk by improved bioavailability/bioenhancing of nutrients. The herbal composition comprises an effective amount of an extract and/or at least one bioactive fraction or powder from herbs such as Asparagus, Withania, Lepidium, Bacopa, Nardostachys, Vetiveria, Pueraria, Emblica, Tinospora etc.; one or more additive selected from Probiotics, decorticated cotton seed extract (DCC), chelated mineral mixture, mineral nutrients, dicalcium phosphate (DCP), dolomite, calcite, vitamins and amino acids to obtain the herbal feed supplement compositions.

Abstract: Provided are a composition and method of increasing health of the human body includes placing a composition inside a solution jar of a solution jar assembly, wherein the composition comprises at least one of a garlic solution comprising garlic extract, ethanol, and water; a 10-undecenoic acid solution comprising 10-undecenoic acid and at least one of water and alcohol; and a Pau d'Arco solution comprising Pau d'Arco extract, corn starch, ethanol, and water, wherein the solution jar assembly includes a device comprising either a radial appliance or a wet-cell battery appliance; a first metal disc connected to the device by a first wire; a solution jar, connected to the device by a second wire, for holding the solution; a second metal disc connected to the solution jar by a third wire; and a connecting loop, located inside a removable lid of the solution jar, connecting the first and third wires and passing through the solution; wherein if the device is the radial appliance, placing the radial appliance in a co

Abstract: A probiotic composition including a probiotic microorganism embedded within a matrix, the matrix substantially maintaining the viability of said microorganisms. The matrix releases said microorganisms into and upon contact with a liquid carrier. The invention includes methods for manufacturing the composition, particular forms of the composition (2) and as apparatus for administration.

Abstract: The invention provides nucleic acids obtained from strains of Bacillus thuringiensis encoding ?-endotoxins having pesticidal activity against insect pests including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acid molecules encoding mutant pesticidal polypeptides, pesticidal compositions, expression cassettes, and transformed microorganisms and plants comprising a nucleic acid molecule of the invention. Such compositions find use in methods for controlling plant pests.

Abstract: A suppository is provided for rectal, vaginal or urethral administration. A method also is provided for the preparation of a suppository for rectal, vaginal or urethral administration. The method uses at least one unsaturated, non-esterified fatty acid in a composition containing a probiotic and an antibiotic.

Abstract: The present invention relates to novel microorganisms having the efficiency of removing an offensive odor from organic waste and the use thereof. More particularly, the novel microorganisms have the effects of preventing or removing the offensive odor from organic waste, killing insects and fungi, preventing decomposition, and promoting digestion and fermentation. The inventive microorganisms have the effects of preventing or removing the offensive odor from organic waste and killing noxious insects and plant pathogenic fungi, can be used as feed additives and antibiotic substitutes, and also are useful for the preparation of fermented healthy foods.

Abstract: Strains of Cryptococcus flavescens which are superior antagonists of F. graminearum for suppression and control of FHB in cereals, particularly in wheat and barley, are described. The strains are prothioconazole tolerant variants of previously described C. flavescens OH 182.9 (NRRL Y-30216). Moreover, these prothioconazole tolerant variants exhibit significantly increased efficacy against F. graminearum in comparison to the parent strain OH 182.9.

Abstract: Nutritional compositions and methods of making and using the nutritional compositions are provided. In a general embodiment, the present disclosure provides a nutritional composition including one or more exogenous nucleotides.

Abstract: Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an immune response by administration of a yeast vehicle and an antigen that is not complexed to the yeast vehicle is disclosed.

Abstract: The present invention relates to a novel monascuspurpurone compound of formula (I): or a pharmaceutically acceptable derivative thereof as described in the specification, the process for preparation of the same, and the composition comprising the same. The uses of a monascuspurpurone compound for promoting adipocyte differentiation, for increasing the activity of PPAR? and/or C/EBP?, for lowering blood glucose, for preventing and/or treating a disease or disorder related to insulin resistance, and for preventing and/or treating metabolic syndrome or its complications are also provided.

Abstract: The object of the invention is the use of Candida saitoana or an active ingredient that is obtained from Candida saitoana as a cosmetic active ingredient, in particular for the detoxification of skin cells. The invention also relates to an active ingredient that is obtained from Candida saitoana, to a production process, as well as to cosmetic compositions that contain this active ingredient, and to a cosmetic personal care process for improving the surface condition of dull and intoxicated skin.

Abstract: The invention relates to a cosmetic and/or dermatological topical composition, of particular use for the preventional and/or treatment of sensitive and/or dry skin, comprising an effective amount of at least one particularly probiotic microorganism and/or a fraction or metabolite thereof in combination with an effective amount of at least one polyunsaturated fatty acid and/or polyunsaturated fatty acid ester and/or a salt or derivative thereof in a physiologically-acceptable vehicle.

Abstract: An extract of the marine algae, Sarcodiotheca, and more particularly Sarcodiotheca gaudichaudii, is described for use in cosmetic compositions. A biofermentation of Sarcodiotheca, such as for example S. gaudichaudii, is also described. This marine bioferment is useful as a skin care active ingredient for anti-aging cosmetic applications, and particularly useful when used in combination with an extracts of red algae, such as Chondrus crispus.

Abstract: A method for producing a dry yeast containing S-adenosyl-L-methionine using a yeast having production capability of S-adenosyl-L-methionine, in which a yeast cell concentrate separated from a cell culture liquid of the yeast is subjected to at least one treatment of (1) a treatment of adding a mineral acid to adjust the pH of the concentrate to 1 to 5, and (2) a treatment of heating the concentrate to 40 to 85° C., and then dried, and a composition for oral ingestion containing a dry yeast produced by the production method, having been molded. A method for producing dry yeast cells containing S-adenosyl-L-methionine, which is useful as a water soluble physiologically active substance, in a high concentration with a good yield at low cost, and a composition for oral ingestion formed by molding a dry yeast produced by the production method can be provided.

Abstract: The invention provides various high mannose glycosylated polypeptides that are useful in a vaccine formulations. The invention also provides methods for making such glycosylated polypeptides and its uses in eliciting HIV-neutralizing antibodies.

Abstract: The present invention relates to use of a probiotic to normalize abnormal inflammation markers. The present invention also relates to use of a probiotic for preventing and/or treating low-grade inflammation. Further, the present invention relates to use of a probiotic for preventing and/or treating disorders and/or diseases relating to low-grade inflammation.

Abstract: It is intended to utilize ?-glucan produced by a bacterium belonging to Aureobasidium sp. From a bacterium belonging to Aureobasidium sp., a mutant with little pigment accumulation is constructed by a mutagenesis means of, for example, irradiating with ultraviolet light or treating with a mutagen. A culture obtained by culturing this mutant in a liquid culture medium is usable as a composition with a large ?-glucan content without showing any intense dark green color caused by the accumulation of melanin-like pigments. This composition may be taken as such as a functional food having the physiologically active functions of the ?-glucan-containing composition. Alternatively, it may be added to foods, drinks. food additives, cosmetics and so on.

Abstract: A process for recovering a protein-containing fermentation agent, comprising (i) forming an aqueous mixture of an organic material and a protein-containing fermentation agent capable of fermenting the organic material to produce ethanol, (ii) fermenting the aqueous mixture to produce ethanol, (iii) recovering from the fermented aqueous mixture an ethanol stream which is rich in ethanol and a co-product stream comprising unfermented organic material, fermentation agent and an aqueous solution of dissolved solids in water, (iv) subjecting the co-product stream to a first separation stage to recover a first stream rich in the unfermented organic material and a second stream rich in the fermentation agent suspended in the aqueous solution, and (v) subjecting the second stream to a second separation step, capable of recovering suspended solids from a liquid, to recover a third stream rich in the fermentation agent and a fourth stream rich in the aqueous solution.

Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.

Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.

Abstract: The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed.

Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.

Abstract: HBsAg is expressed in a Saccharomyces cerevisiae host, carrying a plasmid having a HBsAg coding sequence, wherein the plasmid includes: (1) an upstream promoter from a glyceraldehyde-3-phosphate dehydrogenase gene, for controlling expression of the HBsAg coding sequence; and (2) an ARG3 transcription terminator downstream of the HBsAg coding sequence. The plasmids may also include: (3) a LEU2 selection marker; (4) a 2? plasmid sequence; and (5) an origin of replication functional in Escherichia coli. HBsAg can be expressed in this host, and can be purified for use in the manufacture of vaccines, and in particular for the manufacture of combination vaccines and in new monovalent HBV vaccines e.g. with non-alum adjuvants.

Abstract: This invention provides a method of using red yeast rice fermented product to treat a subject having a disease caused by dengue virus. In one embodiment, the red yeast rice is prepared with the yeast Monascus purpureus.

Abstract: The present invention includes compositions and drying methods for preserving sensitive bioactive materials, such as peptides, proteins, hormones, nucleic acids, antibodies, drugs vaccines, yeast, bacteria (probiotic or otherwise), viruses and/or cell suspensions, in storage. The compositions include a carbohydrates component and a glass enhancer component, wherein the carbohydrate component includes a mixture of di-, oligo- and polysaccharides and the glass enhancer includes ions of organic acid and protein hydrolysates. The composition is prepared by dispersing all the solid components in a solution and then snap-frozen to form small beads, strings or droplets. The preferred drying method of the frozen beads, strings or droplets is initiated by a short purging and structure stabilizing step of the frozen particles under a vacuum pressure of less than <2000 mTORR followed by a primary drying step under vacuum pressure of more than >2000 mTORR and at a desired temperature.

Abstract: This invention concerns a nutraceutical and/or food composition for regulating, among other things, lipid metabolism in humans and animals, and methods of use of said nutraceutical and/or food composition.

Abstract: A molluscicidal composition, comprising: a molluscicide; a molluscicidal activity promoting additive comprising a calcium-containing salt of ethylene disuccinic acid or calcium ions and ethylenediamine disuccinic moieties, having at least 1 mole of calcium per mole of ethylenediamine disuccinic acid; and a carrier material edible to molluscs.

Abstract: The invention relates to the improvement of visual performance, particularly of visual performance in the darkness, by administration of a colorant that is capable of being incorporated into eye tissue and/or causing yellowing of eye tissue, especially carotenoids, such as lutein and zeaxanthin.

Abstract: The invention pertains to the field of probiotic compositions useful for human and/or animal food and health. The invention particularly relates to compositions containing stable probiotic microorganisms during the production of tablets or granules for final use. The works of the applicant of the present invention show that the mortality of probiotic microorganisms during granulation is closely linked with granulation operating conditions and with the characteristics of the selected microorganisms. Said works have led to the establishment of a mathematical expression for defining both the characteristics of the yeast as well as the parameters of the method so that the microorganism losses after granulation are lower than 1 log CFU/g of granulated food.

Abstract: The invention relates to a strain of Saccharomyces cerevisae characterized in that it is selected from strain No. I-3936 deposited on Mar. 4 2008 at the CNCM, strain No. I-3937 deposited on Mar. 4 2008 at the CNCM, strain No. I-3938 deposited on Mar. 4 2008 at the CNCM, and strain No. I-3939 deposited on Mar. 4 2008 at the CNCM. The invention also relates to a phytosanitary composition and to a method for treating or protecting plants against diseases caused by pathogens, using said strain.

Abstract: The present invention is based, in part, on our discovery of compositions and methods that can be used to systemically deplete arginine and thereby treat arginine-dependent cancers. Our studies indicate that administering a composition that depletes arginine directly to the patient's small intestine will provide effective treatment for arginine-dependent cancers. Moreover, the methods can be carried out in such a way that various sources of arginine are restricted and side effects are minimized. For example, to deplete arginine, one can not only administer an arginine-depleting enzyme directly to the intestinal lumen but can also inhibit endogenous production of arginine, reduce arginine production by intestinal bacteria and limit arginine intake. To minimize side effects, one can inhibit protein breakdown, which may occur as a compensatory mechanism, provide systemic NO from a nitric oxide donor, provide a pressor peptide, and/or provide prostacycline or an analog thereof.

Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity.

Abstract: A Small Hive Beetle trap, which replaces the bottom board of beehives, includes a frame having three walls and a top surface, a trap plate, an entry means, and a trapping means. The trapping means provides a dark environment attractive to small hive beetles and contains a small hive beetle attractant made from pollen dough and inoculated with yeast that produces small hive beetle attracting volatiles. The yeast is a biologically pure strain of yeast producing hive beetle attracting volatiles designated yeast spp. NRRL Y-30722.

Abstract: A method for inducing resistance to abiotic stress is provided, comprising applying to the plant an amount of a composition comprising a yeast cell wall effective to prevent or reduce harmful effects of the pathogen. The composition may further include a plant extract derived from Yucca.

Abstract: The present invention relates to compositions and methods for protection against bacterial contamination. The invention provides bactericidal yeast expressing bacteriocin proteins and methods of using the bactericidal yeast.

Abstract: Compositions and methods for protection against bacterial contamination are disclosed Antibacterial proteins and methods of use thereof are also disclosed

Abstract: The present invention is a grain product. The grain product includes a first fraction including bran. The first fraction is milled to a first particle size of less than 500 micrometers. The grain product also includes a second fraction including germ. The second fraction is milled to a second particle size of less than 500 micrometers. The grain product is at least one of: a food product, a nutritional supplement, a dietary supplement, a fiber supplement, a digestive supplement, a functional food, and a medical food.

Abstract: Compositions comprising a (A) dithiino-tetracarboximide of formula (I) and at least one agriculturally beneficial biological control agent (B) are disclosed. A method for curatively or preventively controlling phytopathogenic fungi of plants or crops is disclosed. A method for treating seed and a method for protecting seed are disclosed.

Abstract: The invention includes a formulation comprising: (i) a therapeutically effective amount of at least one antibiotic; and (ii) a therapeutically effective amount of at least one probiotic material. The formulation is prepared in a dosage form for delivery to the gastrointestinal tract. The invention further includes a method of preventing or minimizing the proliferation of Clostridium difficile in the gastrointestinal tract of a mammal undergoing an antibiotic therapy comprising by administration of the formulation of the invention for the duration of the antibiotic therapy; methods of preventing or minimizing the occurrence of antibiotic-associated diarrhea in a mammal undergoing an antibiotic therapy that includes administering the formulation; and methods of preventing or minimizing the occurrence of antibiotic-associated colitis or pseudomembranous colitis in a patient undergoing an antibiotic therapy that includes administering the formulation.

Abstract: The present invention relates to compositions for use in low-birth weight infants. In particular, the compositions are probiotic compositions which are used for achieving full enteral feeding in low birth weight infants. The invention is also concerned with the use of specific probiotics in the manufacture of low-birth weight infant formulations.

Abstract: The invention relates to a controlled release formulation for a probiotic. The formulation contains a hydrophilic agent, an electrolytic agent and a polysaccharide and is in the form of a monolithic tablet for oral delivery to the intestinal system. The probiotic can be lactic acid bacteria.

Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.

Abstract: Compositions and methods for the treatment of intestinal infections. Compositions that include a liquid crystal mixture of an antimicrobial glycerol fatty acid ester and a polyhydric alcohol inhibit the growth of numerous deleterious intestinal pathogenic bacteria, including C. difficile. C. difficile is the causative agent in an increasing number of antibiotic-resistant bacterial infections. The formulations may be administered orally as capsules or soft gels, or alternatively as a enema, colonic, or rectal suppository. When combined with a probiotic supplement, the liquid crystal combinations reported here are able to treat an intestinal bacterial infection effectively and safely, thus promoting general intestinal health.

Abstract: The present invention provides formulations and methods for preventing, suppressing, treating, or controlling pre- or post-harvest disease or decay in plants. In the inventive method, plants are contacted with a formulation including an antagonistic microorganism and a booster composition. The booster composition generally includes about 3 parts Kaolin clay, about 1 part yeast, about 1 part Yucca plant extract, and about 1 part calcium-source material. The antagonistic microorganism may be included in an amount of between about 0.02 parts and about 0.5 parts by weight of the formulation, with about 0.04 parts antagonistic microorganism being preferred in testing to date. The formulation is typically applied to the above ground structures of the plant, including its leaves, flowers, stems, trunk, blossoms and fruit.